<DOC>
	<DOCNO>NCT00395135</DOCNO>
	<brief_summary>The purpose study assess weight loss effect lorcaserin end first year treatment ( Week 52 ) ass ability lorcaserin maintain weight loss end second year treatment ( Week 104 )</brief_summary>
	<brief_title>BLOOM : Behavioral Modification Lorcaserin Overweight Obesity Management</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<criteria>Obese adult BMI 30 45 kg/m2 overweight adult BMI 27 29.9 kg/m2 least one obesityrelated comorbidity ( hypertension , dyslipidemia , cardiovascular disease , glucose intolerance , sleep apnea ) Ability complete 2 year study Diabetes Pregnancy History heart valve disease Serious unstable current past medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Weight loss</keyword>
	<keyword>lorcaserin</keyword>
	<keyword>APD356</keyword>
	<keyword>BLOOM</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Sleep apnea</keyword>
	<keyword>glucose tolerance</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>Arena</keyword>
</DOC>